2 CASES OF GASTRIC-CANCER REMARKABLY REDUCED WITH A COMBINED DOSAGE OF IRSOGLADINE MALEATE PREPARATION AND UFT

  • Authors: T HOSOKAWA, K OGAWA, Y OTANI, T KAJIWARA
  • View Affiliations

  • Published online on: Saturday, January 1, 1994
  • Pages: 93-95
  • DOI: 10.3892/or.1.1.93

Abstract

Irsogladine Maleate intensifies the degree of intercellular contact so we expected that a combination of Irsogladine Maleate and UFT would cause tumor-reducing effect and normalization of the malignant cells. A combination of Irsogladine Maleate and UFT was administered to 2 patients with inoperable gastric cancer (Case 1: An 83-year-old male: Borrmann type I, Case 2: A 93-year-old female: A relatively wide early gastric cancer), marked tumor reduction was obtained in both cases. The doses administered were 4 mg/day of Irsogladine Maleate and 200 mg/day of UFT.
Journal Cover

January 1994
Volume 1 Issue 1

Print ISSN: 1021-335X
Online ISSN:1791-2431

2012 Impact Factor: 2.297
Ranked #36/196 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
HOSOKAWA, T., OGAWA, K., OTANI, Y., & KAJIWARA, T. (1994). 2 CASES OF GASTRIC-CANCER REMARKABLY REDUCED WITH A COMBINED DOSAGE OF IRSOGLADINE MALEATE PREPARATION AND UFT. Oncology Reports, 1(1), 93-95.
MLA
HOSOKAWA, OGAWA, OTANI, and T KAJIWARA. "2 CASES OF GASTRIC-CANCER REMARKABLY REDUCED WITH A COMBINED DOSAGE OF IRSOGLADINE MALEATE PREPARATION AND UFT." Oncology Reports Oncology Reports 1.1 (1994): 93-95.
Chicago
HOSOKAWA, OGAWA, OTANI, and T KAJIWARA. "2 CASES OF GASTRIC-CANCER REMARKABLY REDUCED WITH A COMBINED DOSAGE OF IRSOGLADINE MALEATE PREPARATION AND UFT." Oncology Reports Oncology Reports 1 no. 1 (1994): 93-95.